Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sibofimloc - Enterome/Takeda

Next Previous
Drug Profile

Sibofimloc - Enterome/Takeda

Alternative Names: EB-8018; TAK-018

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Enterome; Takeda
  • Class Anti-inflammatories; Fluorenes; Hepatoprotectants; Ketones; Piperidines; Pyrans; Small molecules; Spiro compounds
  • Mechanism of Action E coli fimH protein inhibitors; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • No development reported Gastrointestinal disorders; Liver disorders

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom (PO)
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Liver-disorders in United Kingdom (PO)
  • 25 Aug 2022 Takeda terminates the phase IIa SYMMETRY trial in Crohn's disease in Austria, United Kingdom, France, Germany, Netherlands and USA (PO) due to sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period (EudraCT2019-000886-19) (NCT03943446)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top